BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRIW
Biofrontera Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.81−0.02 (-1.94%)
Close on Oct 19, 2026
- Market cap
- $10.41M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.1543 (−16.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Biofrontera Inc. grew revenue 17.8% to $46.18M over the twelve months to Jun 30, 2026. Free cash flow was -$7.93M.
Revenue
$46.18M
+17.8% vs. a year earlier
Operating income
-$6.56M
TTM Q2 2026
Free cash flow
-$7.93M
TTM Q2 2026
EPS, diluted
-$0.60
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.41M
- P/E ratio
- –
- Price to sales
- 0.23
- Price to book
- 1.75
- Dividend yield
- –
- Free cash flow yield
- -76.16%
Fundamentals
- Revenue
- $46.18M
- Net income
- -$6.37M
- EPS, diluted
- -$0.60
- Free cash flow
- -$7.93M
- Book value per share
- $0.46
- Diluted shares
- 13M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$46.18M+17.8% YoY
Operating income
-$6.56M
Net income
-$6.37M
EPS, diluted
-$0.60
Free cash flow
-$7.93M
Reported periodTrailing twelve months